Business
Immunome Reports Full Year 2024 Financial Results and Provides Business Update
Topline data for Phase 3 RINGSIDE study of varegacestat in progressing desmoid tumors expected in second half of 2025. First patient dosed in Phase 1
About this update from Immunome, Inc.
[{"type":"text","content":"\n\nTopline data for Phase 3 RINGSIDE study of varegacestat in progressing desmoid tumors expected in second half of 2025.\n\n\nFirst patient dosed in Phase 1 clinical trial evaluating IM-1021, a ROR1-targeted ADC.\n\n\nIND submitted in March 2025 for IM-3050, a FAP-targeted radioligand therapy.\n\n\nProjected cash runway extends into 2027\n\n\n BOTHELL, Wash.--(BUSINESS WIRE)--\nImmunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2024 and provided a business update.\n\n“Immunome’s efficient execution in 2024 laid the foundation for a productive 2025,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer. “We are pleased with the progress of our pipeline and, with multiple programs now in clinical development, we expect that our recent financing will support multiple clinical milestones. We particularly look forward to topline data in the second half of 2025 for the RINGSIDE trial of varegacestat, which we believe will demonstrate significant benefits for patients with desmoid tumors.\n\n“Our highly capable team is achieving our vision of a broad, differentiated portfolio of ADCs. We recently dosed the first patient in the Phase 1 clinical trial of IM-1021, our ROR1-targeted ADC. Three additional novel ADCs, IM-1617, IM-1335 and IM-1340, are in IND-enabling manufacturing, with additional discovery-stage programs under evaluation. We recently submitted the IND for IM-3050, our FAP radiotherapy, and anticipate initiating a Phase 1 clinical trial for that program later this year.”\n\nPipeline Highlights\n\nVaregacestat: Full enrollment for the Phase 3 RINGSIDE Part B study of varegacestat for the treatment of desmoid tumors was completed in February 2024, and Immunome expects to report topline data for RINGSIDE Part B in the second half of 2025. In parallel, Immunome is performing the manufacturing and pharmacology work required to support a new drug application filing for varegacestat.\n\nIM-1021: The Phase 1 clinical trial of IM-1021 is ongoing, with the first patient dosed in February 2025. The Phase 1 trial is an open-label, multicenter dose-escalation and expansion study that is expected to include participants with advanced B-cell lymphomas and advanced solid...